Document ID: docfile:adfbaf1c-52b7-4913-af8e-638df5b94150
Source Database: euc_mergers
Source URL: https://ec.europa.eu/competition/mergers/cases1/202215/M_10657_8263643_109_3.pdf
Title: SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS
Date: 2022-04-04T00:00:00.000+02:00
Metadata: {"caseNumber": "M.10657", "caseInstrument": "M", "caseTitle": "SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS", "caseLastDecisionDate": "2022-04-03T22:00:00.000Z", "caseCompanies": ["SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS"]}

# **EUROPEAN COMMISSION DG Competition**

# Case M.10657 - SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS

Only the English text is available and authentic.

#### **REGULATION (EC) No 139/2004 MERGER PROCEDURE**

#### Article 6(1)(b) NON-OPPOSITION Date: 04/04/2022

In electronic form on the EUR-Lex website under document number 32022M10657

# **EUROPEAN COMMISSION**

Brussels, 4.4.2022 C(2022) 2246 final

#### **PUBLIC VERSION**

Samsung BioLogics Co. Ltd. 300 Songdo bio-daero, Yeonsu-gu 21987 Incheon Republic of Korea

Subject: Case M.10657 - SAMSUNG BIOLOGICS / SAMSUNG BIOEPIS Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC) No 139/2004 and Article 57 of the Agreement on the European Economic Area

Dear Sir or Madam,

    1. On 11 March 2022, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Samsung BioLogics Co. Ltd. (“Samsung BioLogics”, Republic of Korea), a company controlled by the Samsung Group (Republic of Korea), acquires within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Samsung Bioepis Co. Ltd. (“Bioepis, Republic of Korea”), a company currently jointly controlled by Biogen Therapeutics Inc. (USA) and Samsung BioLogics. The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are the following:

    − Samsung BioLogics is a company active in the development and manufacturing of biopharmaceutical products worldwide,

    − Bioepis is a company active in the development and commercialisation of biosimilar medicines.

[^]: 1 OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology of the TFEU will be used throughout this decision.

[^]: 2 OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).

[^]: 3 Publication in the Official Journal of the European Union No C 123, 18.03.2022, p. 46.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.

    3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(d) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.

    4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

For the Commission

(Signed) Olivier GUERSENT Director-General

[^]: 4 OJ C 366, 14.12.2013, p. 5.

[^]: 2